Enhancing cognition in neurological disorders

Potential usefulness of 5-HT6 antagonists

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

It is widely recognized that cognitive dysfunction is among the most debilitating symptoms of many neuropsychiatric disorders, including Alzheimer's disease and schizophrenia. Accordingly, there is a critical need for new drugs with procognitive activity. Recently, the role of the neurotransmitter serotonin (5-HT) and its receptor subtypes in cognition has emerged, and as a result, the focus on 5-HT receptor subtypes as targets for memory enhancement has increased. Among the 5-HT subtypes, the 5-HT6 receptor may be a particularly attractive target given its almost exclusive localization in the brain and its expression in both limbic areas and other brain regions known to be critical to cognition. Novel ligands with selective affinity for 5-HT 6 receptors would be predicted to have a low incidence of peripheral side effects and to potentially address both cognitive and noncognitive symptoms (e.g., anxiety, depression) of neuropsychiatric disorders. To date, several preclinical studies of 5-HT6 antagonists in rodent models have indeed provided evidence of cognitive enhancement (especially in aged and pharmacologically impaired rats), as well as anxiolytic and antidepressant effects. Accordingly, several 5-HT6 antagonists are currently in clinical trials for the treatment of neuropsychiatric disorders. The purpose of this review is to provide a brief overview of the 5-HT6-related pharmacological approaches designed to enhance memory function.

Original languageEnglish (US)
Pages (from-to)969-975
Number of pages7
JournalDrugs of the Future
Volume34
Issue number12
DOIs
StatePublished - Jan 1 2009

Fingerprint

Serotonin Receptors
Nervous System Diseases
Cognition
Serotonin
Neurobehavioral Manifestations
Anti-Anxiety Agents
Brain
Antidepressive Agents
Neurotransmitter Agents
Rodentia
Schizophrenia
Alzheimer Disease
Anxiety
Clinical Trials
Pharmacology
Depression
Ligands
Incidence
Pharmaceutical Preparations
serotonin 6 receptor

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Enhancing cognition in neurological disorders : Potential usefulness of 5-HT6 antagonists. / Wilson, Christina A; Terry, Alvin V.

In: Drugs of the Future, Vol. 34, No. 12, 01.01.2009, p. 969-975.

Research output: Contribution to journalReview article

@article{11d4a29b96724c6094a992806d0f32a5,
title = "Enhancing cognition in neurological disorders: Potential usefulness of 5-HT6 antagonists",
abstract = "It is widely recognized that cognitive dysfunction is among the most debilitating symptoms of many neuropsychiatric disorders, including Alzheimer's disease and schizophrenia. Accordingly, there is a critical need for new drugs with procognitive activity. Recently, the role of the neurotransmitter serotonin (5-HT) and its receptor subtypes in cognition has emerged, and as a result, the focus on 5-HT receptor subtypes as targets for memory enhancement has increased. Among the 5-HT subtypes, the 5-HT6 receptor may be a particularly attractive target given its almost exclusive localization in the brain and its expression in both limbic areas and other brain regions known to be critical to cognition. Novel ligands with selective affinity for 5-HT 6 receptors would be predicted to have a low incidence of peripheral side effects and to potentially address both cognitive and noncognitive symptoms (e.g., anxiety, depression) of neuropsychiatric disorders. To date, several preclinical studies of 5-HT6 antagonists in rodent models have indeed provided evidence of cognitive enhancement (especially in aged and pharmacologically impaired rats), as well as anxiolytic and antidepressant effects. Accordingly, several 5-HT6 antagonists are currently in clinical trials for the treatment of neuropsychiatric disorders. The purpose of this review is to provide a brief overview of the 5-HT6-related pharmacological approaches designed to enhance memory function.",
author = "Wilson, {Christina A} and Terry, {Alvin V}",
year = "2009",
month = "1",
day = "1",
doi = "10.1358/dof.2009.034.12.1416986",
language = "English (US)",
volume = "34",
pages = "969--975",
journal = "Drugs of the Future",
issn = "0377-8282",
publisher = "Prous Science",
number = "12",

}

TY - JOUR

T1 - Enhancing cognition in neurological disorders

T2 - Potential usefulness of 5-HT6 antagonists

AU - Wilson, Christina A

AU - Terry, Alvin V

PY - 2009/1/1

Y1 - 2009/1/1

N2 - It is widely recognized that cognitive dysfunction is among the most debilitating symptoms of many neuropsychiatric disorders, including Alzheimer's disease and schizophrenia. Accordingly, there is a critical need for new drugs with procognitive activity. Recently, the role of the neurotransmitter serotonin (5-HT) and its receptor subtypes in cognition has emerged, and as a result, the focus on 5-HT receptor subtypes as targets for memory enhancement has increased. Among the 5-HT subtypes, the 5-HT6 receptor may be a particularly attractive target given its almost exclusive localization in the brain and its expression in both limbic areas and other brain regions known to be critical to cognition. Novel ligands with selective affinity for 5-HT 6 receptors would be predicted to have a low incidence of peripheral side effects and to potentially address both cognitive and noncognitive symptoms (e.g., anxiety, depression) of neuropsychiatric disorders. To date, several preclinical studies of 5-HT6 antagonists in rodent models have indeed provided evidence of cognitive enhancement (especially in aged and pharmacologically impaired rats), as well as anxiolytic and antidepressant effects. Accordingly, several 5-HT6 antagonists are currently in clinical trials for the treatment of neuropsychiatric disorders. The purpose of this review is to provide a brief overview of the 5-HT6-related pharmacological approaches designed to enhance memory function.

AB - It is widely recognized that cognitive dysfunction is among the most debilitating symptoms of many neuropsychiatric disorders, including Alzheimer's disease and schizophrenia. Accordingly, there is a critical need for new drugs with procognitive activity. Recently, the role of the neurotransmitter serotonin (5-HT) and its receptor subtypes in cognition has emerged, and as a result, the focus on 5-HT receptor subtypes as targets for memory enhancement has increased. Among the 5-HT subtypes, the 5-HT6 receptor may be a particularly attractive target given its almost exclusive localization in the brain and its expression in both limbic areas and other brain regions known to be critical to cognition. Novel ligands with selective affinity for 5-HT 6 receptors would be predicted to have a low incidence of peripheral side effects and to potentially address both cognitive and noncognitive symptoms (e.g., anxiety, depression) of neuropsychiatric disorders. To date, several preclinical studies of 5-HT6 antagonists in rodent models have indeed provided evidence of cognitive enhancement (especially in aged and pharmacologically impaired rats), as well as anxiolytic and antidepressant effects. Accordingly, several 5-HT6 antagonists are currently in clinical trials for the treatment of neuropsychiatric disorders. The purpose of this review is to provide a brief overview of the 5-HT6-related pharmacological approaches designed to enhance memory function.

UR - http://www.scopus.com/inward/record.url?scp=84930537141&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930537141&partnerID=8YFLogxK

U2 - 10.1358/dof.2009.034.12.1416986

DO - 10.1358/dof.2009.034.12.1416986

M3 - Review article

VL - 34

SP - 969

EP - 975

JO - Drugs of the Future

JF - Drugs of the Future

SN - 0377-8282

IS - 12

ER -